RESUMO
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a new category of oral antidiabetics recently indicated for the treatment of type 2 diabetes. Their mechanism of action (inhibition of renal reabsorption of glucose) and the fact that they do not induce hypoglycemia (as monotherapy) make their clinical use interesting. Various adverse events have however been reported regarding these drugs with the euglycemic ketoacidosis being the most serious. In this article we aim to review the possible mechanism of this side effect and recommendations for use of SGLT2 inhibitors by means of a case report.
Les inhibiteurs du SGLT2 (sodium-glucose cotransporter 2) sont une nouvelle catégorie d'antidiabétiques oraux recommandés récemment pour le traitement du diabète de type 2. Leur mécanisme d'action (inhibition de la réabsorption du glucose au niveau rénal) et le fait qu'ils n'induisent pas d'hypoglycémie (en monothérapie) rendent leur profil intéressant. Cependant, plusieurs effets indésirables ont été décrits depuis leur apparition, dont le plus grave est une acidocétose euglycémique. Dans cet article, nous revoyons à la lumière d'un cas les mécanismes probables de cet effet secondaire et les recommandations d'utilisation des inhibiteurs du SGLT2.
Assuntos
Hipoglicemiantes/efeitos adversos , Cetose/induzido quimicamente , Inibidores do Transportador 2 de Sódio-Glicose , Glicemia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Humanos , Hipoglicemiantes/farmacologia , Transportador 2 de Glucose-SódioRESUMO
The increasing prevalence of obesity and diabetes represents one of the major public health problem in developed countries, leading to intensive research on the causes and intervention possibilities. Over the last years, intestinal flora became a first-line topic in this research: the development of techniques in molecular biology allowed a more specific approach and the elaboration of a genetic library of the intestinal microbiota. This article summarises acquired knowledge and hypothesis related to the potential role of intestinal microbiota in the development of obesity and insulin resistance.
